Visen Pharma Announces Positive Results From Phase 3 Trial Of Once-Weekly Lonapegsomatropin In Children With Growth Hormone Deficiency
Visen Pharmaceuticals, An Innovative Biopharmaceutical Company Focused On Endocrine Diseases, Announced Positive Top-Line Results From Its Pivotal Phase 3 Trial, A Randomized, Open-Label, Active-Controlled Trial That Compared Lonapegsomatropin (Transcon Hgh), A Once-Weekly Administered Long-Acting Drug That Delivers Unmodified Growth Hormone, To A Daily Human Growth Hormone (Hgh) In Children With Growth Hormone Deficiency (Ghd) In China.
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!